For the Inventor, By the Inventor

Enter assignee name

Youseong-gu, South Korea

Legochem Biosciences, Inc.

USPTO Granted Patents = 25

CIPO Patents = 1

EPO Patents = 6

Trademarks = 1

Forward Citations = 126

Loading Chart...

Loading Chart...

96 inventors (with patents filed for the assignee):

Yong Zu Kim (22 out of 30 patents)

Jeiwook Chae (15 out of 21 patents)

Chul-Woong Chung (15 out of 17 patents)

4. Ho Young Song (14 out of 27 patents)

5. Yeong Soo Oh (12 out of 19 patents)

6. Yun Hee Park (12 out of 12 patents)

7. Sung Ho Woo (10 out of 22 patents)

8. Tae Kyo Park (10 out of 16 patents)

9. Sung Min Kim (9 out of 16 patents)

10. Ji Young Min (8 out of 8 patents)

11. Jeong Hee Ryu (8 out of 9 patents)

12. Kyu Man Oh (8 out of 8 patents)

13. Sang Eun Chae (8 out of 14 patents)

14. Young Lag Cho (8 out of 12 patents)

15. Hyang Sook Lee (8 out of 18 patents)

25 patents: Sort by Forward Citations

1. 11975076 - Antibody-drug conjugates comprising branched linkers and methods related thereto (2024-05-07),

2. 11827703 - Compositions and methods related to anti-CD19 antibody drug conjugates (2023-11-28),

3. 11707533 - Antibody-drug conjugate comprising antibody against human ROR1 and use for the same (2023-07-25),

4. 11654197 - Pyrrolobenzodiazepine dimer prodrug and ligand-linker conjugate compound of the same (2023-05-23),

5. 11548883 - Compounds as autotaxin inhibitors and pharmaceutical compositions comprising the same (2023-01-10),

6. 11413353 - Conjugates comprising self-immolative groups and methods related thereto (2022-08-16),

7. 11173214 - Antibody-drug conjugates comprising branched linkers and methods related thereto (2021-11-16),

8. 11167040 - Conjugates comprising peptide groups and methods related thereto (2021-11-09),

9. 10980890 - Compounds comprising self-immolative group (2021-04-20),

10. 10961242 - Compounds as autotaxin inhibitors and pharmaceutical compositions comprising the same (2021-03-30),

11. 10583197 - Antibody-active agent conjugates and methods of use (2020-03-10),

12. 10383949 - Compounds comprising self-immolative group (2019-08-20),

13. 10273235 - Compositions and methods for inhibiting β-lactamase (2019-04-30),

14. 10183997 - Compositions and methods related to anti-CD19 antibody drug conjugates (2019-01-22),

15. 10118965 - Compositions and methods related to anti-EGFR antibody drug conjugates (2018-11-06),

LegoChem Biosciences, Inc. is a biopharmaceutical company that specializes in novel therapeutics discovery through its diverse pipeline in oncology, immunology, and infectious diseases. Founded in 2006 and headquartered in Daejeon, South Korea, LegoChem Biosciences focuses on developing innovative small molecule drugs by integrating its cutting-edge medicinal chemistry, proprietary ADC technology, and unique target binding platform. With a strong commitment to improving patient outcomes, LegoChem Biosciences aims to deliver breakthrough treatments to address unmet medical needs globally.

This text is generated by artificial intelligence and may not be accurate.

Company Badge

USPTO Data Jan 1 1976 - Dec 30 2025

25 Patents

#1 in Youseong-gu

#511 in South Korea

#24,953 in the World

Youseong-gu, South Korea

Legochem Biosciences, Inc.

Forward Citations = 126

96 inventors:

Yong Zu Kim (22 out of 30 patents)

Jeiwook Chae (15 out of 21 patents)

Chul-Woong Chung (15 out of 17 patents)

4. Ho Young Song (14 out of 27 patents)

5. Yeong Soo Oh (12 out of 19 patents)

Please report any incorrect information to support@idiyas.com

Loading…